#METABOLOMICS WORKBENCH Fpf56_20240502_064525 DATATRACK_ID:4810 STUDY_ID:ST003205 ANALYSIS_ID:AN005257 PROJECT_ID:PR001998
VERSION             	1
CREATED_ON             	May 14, 2024, 1:02 pm
#PROJECT
PR:PROJECT_TITLE                 	CAR-T therapy metabolomic study
PR:PROJECT_SUMMARY               	Plasma metabolomics analysis was performed on 44 patients with
PR:PROJECT_SUMMARY               	relapsed/refractory B-cell non Hodgkin lymphoma (r/r/B-NHL) infused with
PR:PROJECT_SUMMARY               	approved CD19.CAR-T cell products at the time of pre-lymphodepletion (PLD) and
PR:PROJECT_SUMMARY               	at day +1, +7, and +30 after CAR-T cell infusion. At the PLD time point, a
PR:PROJECT_SUMMARY               	metabolic profile characterized by high lipoproteins and lactate and low glucose
PR:PROJECT_SUMMARY               	contributed to poor outcome prediction in association with high lactate
PR:PROJECT_SUMMARY               	dehydrogenase levels. At day+1, higher plasma levels of lipid metabolism
PR:PROJECT_SUMMARY               	products and lower glucose and glycoproteins levels were observed in tisa-cel-
PR:PROJECT_SUMMARY               	compared to axi-cel-treated patients. At day+30, a higher content of lactate, as
PR:PROJECT_SUMMARY               	well as phenylalanine/tryptophan amino acids which represent the precursors of
PR:PROJECT_SUMMARY               	the key players of myeloid derived suppressor cells were found in patients who
PR:PROJECT_SUMMARY               	relapsed over time compared to patients who maintained complete remission until
PR:PROJECT_SUMMARY               	1-year. Our data show complex metabolomic changes that track the evolution of
PR:PROJECT_SUMMARY               	the disease and drug activity in the first 30 days of CAR-T cell therapy.
PR:PROJECT_SUMMARY               	Notably, specific metabolic signatures at PLD and day+30, together with a day+30
PR:PROJECT_SUMMARY               	metabolic profile related to myeloid immunosuppression, are associated with poor
PR:PROJECT_SUMMARY               	outcome.
PR:INSTITUTE                     	UNIVERSITY OF SALENTO
PR:DEPARTMENT                    	D.i.S.T.e.B.A.
PR:LABORATORY                    	General and Inorganic Chemistry
PR:LAST_NAME                     	FANIZZI
PR:FIRST_NAME                    	FRANCESCO PAOLO
PR:ADDRESS                       	Prov.Le Lecce-Monteroni - Centro Ecotekne, LECCE, LECCE, 73100, Italy
PR:EMAIL                         	fp.fanizzi@unisalento.it
PR:PHONE                         	++39-0832-299265
#STUDY
ST:STUDY_TITLE                   	Metabolic profile evolution in relapsed/refractory B-NHL patients treated with
ST:STUDY_TITLE                   	CD19.CAR-T cell therapy and implications in clinical outcome
ST:STUDY_SUMMARY                 	Plasma metabolomics analysis was performed on 44 patients with
ST:STUDY_SUMMARY                 	relapsed/refractory B-cell non Hodgkin lymphoma (r/r/B-NHL) infused with
ST:STUDY_SUMMARY                 	approved CD19.CAR-T cell products at the time of pre-lymphodepletion (PLD) and
ST:STUDY_SUMMARY                 	at day +1, +7, and +30 after CAR-T cell infusion. At the PLD time point, a
ST:STUDY_SUMMARY                 	metabolic profile characterized by high lipoproteins and lactate and low glucose
ST:STUDY_SUMMARY                 	contributed to poor outcome prediction in association with high lactate
ST:STUDY_SUMMARY                 	dehydrogenase levels. At day+1, higher plasma levels of lipid metabolism
ST:STUDY_SUMMARY                 	products and lower glucose and glycoproteins levels were observed in tisa-cel-
ST:STUDY_SUMMARY                 	compared to axi-cel-treated patients. At day+30, a higher content of lactate, as
ST:STUDY_SUMMARY                 	well as phenylalanine/tryptophan amino acids which represent the precursors of
ST:STUDY_SUMMARY                 	the key players of myeloid derived suppressor cells were found in patients who
ST:STUDY_SUMMARY                 	relapsed over time compared to patients who maintained complete remission until
ST:STUDY_SUMMARY                 	1-year. Our data show complex metabolomic changes that track the evolution of
ST:STUDY_SUMMARY                 	the disease and drug activity in the first 30 days of CAR-T cell therapy.
ST:STUDY_SUMMARY                 	Notably, specific metabolic signatures at PLD and day+30, together with a day+30
ST:STUDY_SUMMARY                 	metabolic profile related to myeloid immunosuppression, are associated with poor
ST:STUDY_SUMMARY                 	outcome.
ST:INSTITUTE                     	UNIVERSITY OF SALENTO
ST:DEPARTMENT                    	D.i.S.T.e.B.A.
ST:LABORATORY                    	General and Inorganic Chemistry
ST:LAST_NAME                     	FANIZZI
ST:FIRST_NAME                    	FRANCESCO PAOLO
ST:ADDRESS                       	Prov.Le Lecce-Monteroni - Centro Ecotekne
ST:EMAIL                         	fp.fanizzi@unisalento.it
ST:STUDY_TYPE                    	NMR Metabolomic
ST:PHONE                         	++39-0832-299265
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
#FACTORS
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	-	CAR-1-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=108; Lactate dehydrogenase (U/L)=273; FERRITIN (ng/mL)=11; PCR (mg/dL)=1.5; RAW_FILE_NAME(Raw_File_Name)=CAR-1-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-2-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=391; Lactate dehydrogenase (U/L)=836; FERRITIN (ng/mL)=6980; PCR (mg/dL)=14.73; RAW_FILE_NAME(Raw_File_Name)=CAR-2-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-3-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=152; Lactate dehydrogenase (U/L)=220; FERRITIN (ng/mL)=242; PCR (mg/dL)=1.22; RAW_FILE_NAME(Raw_File_Name)=CAR-3-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-4-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=144; Lactate dehydrogenase (U/L)=521; FERRITIN (ng/mL)=200; PCR (mg/dL)=1.87; RAW_FILE_NAME(Raw_File_Name)=CAR-4-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-5-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=329; Lactate dehydrogenase (U/L)=457; FERRITIN (ng/mL)=152; PCR (mg/dL)=0.62; RAW_FILE_NAME(Raw_File_Name)=CAR-5-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-7-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=68; Lactate dehydrogenase (U/L)=290; FERRITIN (ng/mL)=470; PCR (mg/dL)=5.41; RAW_FILE_NAME(Raw_File_Name)=CAR-7-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-9-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=93; Lactate dehydrogenase (U/L)=470; FERRITIN (ng/mL)=163; PCR (mg/dL)=0.08; RAW_FILE_NAME(Raw_File_Name)=CAR-9-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-10-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=139; Lactate dehydrogenase (U/L)=214; FERRITIN (ng/mL)=1737; PCR (mg/dL)=18.33; RAW_FILE_NAME(Raw_File_Name)=CAR-10-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-11-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=68; Lactate dehydrogenase (U/L)=497; FERRITIN (ng/mL)=131; PCR (mg/dL)=1.47; RAW_FILE_NAME(Raw_File_Name)=CAR-11-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-12-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=190; Lactate dehydrogenase (U/L)=227; FERRITIN (ng/mL)=1169; PCR (mg/dL)=0.06; RAW_FILE_NAME(Raw_File_Name)=CAR-12-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-13-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=117; Lactate dehydrogenase (U/L)=151; FERRITIN (ng/mL)=1258; PCR (mg/dL)=1.21; RAW_FILE_NAME(Raw_File_Name)=CAR-13-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-15-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=86; Lactate dehydrogenase (U/L)=161; FERRITIN (ng/mL)=138; PCR (mg/dL)=7.66; RAW_FILE_NAME(Raw_File_Name)=CAR-15-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-16-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=193; Lactate dehydrogenase (U/L)=153; FERRITIN (ng/mL)=22; PCR (mg/dL)=0.29; RAW_FILE_NAME(Raw_File_Name)=CAR-16-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-17-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=125; Lactate dehydrogenase (U/L)=357; FERRITIN (ng/mL)=322; PCR (mg/dL)=0.43; RAW_FILE_NAME(Raw_File_Name)=CAR-17-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-18-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=176; Lactate dehydrogenase (U/L)=281; FERRITIN (ng/mL)=294; PCR (mg/dL)=4.88; RAW_FILE_NAME(Raw_File_Name)=CAR-18-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-19-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=215; Lactate dehydrogenase (U/L)=231; FERRITIN (ng/mL)=293; PCR (mg/dL)=1.2; RAW_FILE_NAME(Raw_File_Name)=CAR-19-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-21-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=176; Lactate dehydrogenase (U/L)=1566; FERRITIN (ng/mL)=469; PCR (mg/dL)=2.35; RAW_FILE_NAME(Raw_File_Name)=CAR-21-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-28-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=57; Lactate dehydrogenase (U/L)=903; FERRITIN (ng/mL)=1828; PCR (mg/dL)=19.36; RAW_FILE_NAME(Raw_File_Name)=CAR-28-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-32-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=EDEMA; TRIGLYCERIDES (mg/dL)=34; Lactate dehydrogenase (U/L)=179; FERRITIN (ng/mL)=27; PCR (mg/dL)=0.44; RAW_FILE_NAME(Raw_File_Name)=CAR-32-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-33_+1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=194; Lactate dehydrogenase (U/L)=168; FERRITIN (ng/mL)=549; PCR (mg/dL)=0.53; RAW_FILE_NAME(Raw_File_Name)=CAR-33_+1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-33_+30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=153; Lactate dehydrogenase (U/L)=324; FERRITIN (ng/mL)=218; PCR (mg/dL)=0.33; RAW_FILE_NAME(Raw_File_Name)=CAR-33_+30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-33_+7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-33_+7D
SUBJECT_SAMPLE_FACTORS           	-	CAR-33-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=250; Lactate dehydrogenase (U/L)=168; FERRITIN (ng/mL)=457; PCR (mg/dL)=0.08; RAW_FILE_NAME(Raw_File_Name)=CAR-33-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-38_+1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=154; Lactate dehydrogenase (U/L)=694; FERRITIN (ng/mL)=1032; PCR (mg/dL)=14.89; RAW_FILE_NAME(Raw_File_Name)=CAR-38_+1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-38_+30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=159; Lactate dehydrogenase (U/L)=427; FERRITIN (ng/mL)=207; PCR (mg/dL)=0.27; RAW_FILE_NAME(Raw_File_Name)=CAR-38_+30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-38_+7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-38_+7D
SUBJECT_SAMPLE_FACTORS           	-	CAR-38-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=222; Lactate dehydrogenase (U/L)=261; FERRITIN (ng/mL)=435; PCR (mg/dL)=0.11; RAW_FILE_NAME(Raw_File_Name)=CAR-38-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-40_+1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=178; Lactate dehydrogenase (U/L)=532; FERRITIN (ng/mL)=1457; PCR (mg/dL)=8.42; RAW_FILE_NAME(Raw_File_Name)=CAR-40_+1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-40_+30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=289; Lactate dehydrogenase (U/L)=663; FERRITIN (ng/mL)=1421; PCR (mg/dL)=1.62; RAW_FILE_NAME(Raw_File_Name)=CAR-40_+30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-40_+7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-40_+7D
SUBJECT_SAMPLE_FACTORS           	-	40-E	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=98; Lactate dehydrogenase (U/L)=185; FERRITIN (ng/mL)=13; PCR (mg/dL)=0.15; RAW_FILE_NAME(Raw_File_Name)=40-E
SUBJECT_SAMPLE_FACTORS           	-	CAR-43_+1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=90; Lactate dehydrogenase (U/L)=158; FERRITIN (ng/mL)=35; PCR (mg/dL)=0.17; RAW_FILE_NAME(Raw_File_Name)=CAR-43_+1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-43_+30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=72; Lactate dehydrogenase (U/L)=292; FERRITIN (ng/mL)=10; PCR (mg/dL)=0.12; RAW_FILE_NAME(Raw_File_Name)=CAR-43_+30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-43_+7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-43_+7D
SUBJECT_SAMPLE_FACTORS           	-	43-E	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=178; Lactate dehydrogenase (U/L)=474; FERRITIN (ng/mL)=1389; PCR (mg/dL)=0.39; RAW_FILE_NAME(Raw_File_Name)=43-E
SUBJECT_SAMPLE_FACTORS           	-	CAR-44_+1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=156; Lactate dehydrogenase (U/L)=224; FERRITIN (ng/mL)=517; PCR (mg/dL)=1.23; RAW_FILE_NAME(Raw_File_Name)=CAR-44_+1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-44_+30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=175; Lactate dehydrogenase (U/L)=486; FERRITIN (ng/mL)=606; PCR (mg/dL)=0.38; RAW_FILE_NAME(Raw_File_Name)=CAR-44_+30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-44_+7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-44_+7D
SUBJECT_SAMPLE_FACTORS           	-	CAR-44-A	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=118; Lactate dehydrogenase (U/L)=193; FERRITIN (ng/mL)=366; PCR (mg/dL)=0.1; RAW_FILE_NAME(Raw_File_Name)=CAR-44-A
SUBJECT_SAMPLE_FACTORS           	-	CAR-45_+1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=91; Lactate dehydrogenase (U/L)=197; FERRITIN (ng/mL)=1351; PCR (mg/dL)=17.79; RAW_FILE_NAME(Raw_File_Name)=CAR-45_+1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-45_+30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=212; Lactate dehydrogenase (U/L)=141; FERRITIN (ng/mL)=1513; PCR (mg/dL)=0.64; RAW_FILE_NAME(Raw_File_Name)=CAR-45_+30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-45_+7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-45_+7D
SUBJECT_SAMPLE_FACTORS           	-	45-E	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=134; Lactate dehydrogenase (U/L)=195; FERRITIN (ng/mL)=508; PCR (mg/dL)=2.23; RAW_FILE_NAME(Raw_File_Name)=45-E
SUBJECT_SAMPLE_FACTORS           	-	CAR-46_+1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=121; Lactate dehydrogenase (U/L)=131; FERRITIN (ng/mL)=259; PCR (mg/dL)=1.24; RAW_FILE_NAME(Raw_File_Name)=CAR-46_+1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-46_+30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=192; Lactate dehydrogenase (U/L)=160; FERRITIN (ng/mL)=55; PCR (mg/dL)=0.09; RAW_FILE_NAME(Raw_File_Name)=CAR-46_+30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-46_+7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-46_+7D
SUBJECT_SAMPLE_FACTORS           	-	46-E	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=156; Lactate dehydrogenase (U/L)=176; FERRITIN (ng/mL)=167; PCR (mg/dL)=0.1; RAW_FILE_NAME(Raw_File_Name)=46-E
SUBJECT_SAMPLE_FACTORS           	-	CAR-47_+1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=95; Lactate dehydrogenase (U/L)=153; FERRITIN (ng/mL)=307; PCR (mg/dL)=0.93; RAW_FILE_NAME(Raw_File_Name)=CAR-47_+1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-47_+30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=134; Lactate dehydrogenase (U/L)=197; FERRITIN (ng/mL)=281; PCR (mg/dL)=0.17; RAW_FILE_NAME(Raw_File_Name)=CAR-47_+30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-47_+7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-47_+7D
SUBJECT_SAMPLE_FACTORS           	-	47-E	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=139; Lactate dehydrogenase (U/L)=188; FERRITIN (ng/mL)=225; PCR (mg/dL)=0.19; RAW_FILE_NAME(Raw_File_Name)=47-E
SUBJECT_SAMPLE_FACTORS           	-	CAR-51_+1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=189; Lactate dehydrogenase (U/L)=196; FERRITIN (ng/mL)=146; PCR (mg/dL)=0.81; RAW_FILE_NAME(Raw_File_Name)=CAR-51_+1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-51_+30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=317; Lactate dehydrogenase (U/L)=415; FERRITIN (ng/mL)=53; PCR (mg/dL)=0.26; RAW_FILE_NAME(Raw_File_Name)=CAR-51_+30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-51_+7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-51_+7D
SUBJECT_SAMPLE_FACTORS           	-	51-E	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=165; Lactate dehydrogenase (U/L)=285; FERRITIN (ng/mL)=72; PCR (mg/dL)=0.42; RAW_FILE_NAME(Raw_File_Name)=51-E
SUBJECT_SAMPLE_FACTORS           	-	CAR-53 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=188; Lactate dehydrogenase (U/L)=279; FERRITIN (ng/mL)=1319; PCR (mg/dL)=10.13; RAW_FILE_NAME(Raw_File_Name)=CAR-53 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-53 +30D	Time point:After 30 Days post-infusion (30D)  (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=150; Lactate dehydrogenase (U/L)=282; FERRITIN (ng/mL)=252; PCR (mg/dL)=0.17; RAW_FILE_NAME(Raw_File_Name)=CAR-53 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-53 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-53 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR53-ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=99; Lactate dehydrogenase (U/L)=210; FERRITIN (ng/mL)=435; PCR (mg/dL)=0.08; RAW_FILE_NAME(Raw_File_Name)=CAR53-ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-55 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=159; Lactate dehydrogenase (U/L)=176; FERRITIN (ng/mL)=327; PCR (mg/dL)=0.63; RAW_FILE_NAME(Raw_File_Name)=CAR-55 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR55-ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=240; Lactate dehydrogenase (U/L)=149; FERRITIN (ng/mL)=255; PCR (mg/dL)=0.54; RAW_FILE_NAME(Raw_File_Name)=CAR55-ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-57 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=95; Lactate dehydrogenase (U/L)=202; FERRITIN (ng/mL)=220; PCR (mg/dL)=0.74; RAW_FILE_NAME(Raw_File_Name)=CAR-57 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-57 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=108; Lactate dehydrogenase (U/L)=291; FERRITIN (ng/mL)=59; PCR (mg/dL)=0.25; RAW_FILE_NAME(Raw_File_Name)=CAR-57 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-57 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-57 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR57-ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=104; Lactate dehydrogenase (U/L)=209; FERRITIN (ng/mL)=175; PCR (mg/dL)=0.23; RAW_FILE_NAME(Raw_File_Name)=CAR57-ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-58 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=206; Lactate dehydrogenase (U/L)=329; FERRITIN (ng/mL)=194; PCR (mg/dL)=2.29; RAW_FILE_NAME(Raw_File_Name)=CAR-58 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-58 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=181; Lactate dehydrogenase (U/L)=569; FERRITIN (ng/mL)=64; PCR (mg/dL)=0.1; RAW_FILE_NAME(Raw_File_Name)=CAR-58 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-58 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-58 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR58-ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=228; Lactate dehydrogenase (U/L)=312; FERRITIN (ng/mL)=45; PCR (mg/dL)=0.26; RAW_FILE_NAME(Raw_File_Name)=CAR58-ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-59 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=77; Lactate dehydrogenase (U/L)=142; FERRITIN (ng/mL)=66; PCR (mg/dL)=0.55; RAW_FILE_NAME(Raw_File_Name)=CAR-59 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-59 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=58; Lactate dehydrogenase (U/L)=167; FERRITIN (ng/mL)=11; PCR (mg/dL)=0.43; RAW_FILE_NAME(Raw_File_Name)=CAR-59 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-59 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-59 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR59-ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=99; Lactate dehydrogenase (U/L)=164; FERRITIN (ng/mL)=282; PCR (mg/dL)=0.27; RAW_FILE_NAME(Raw_File_Name)=CAR59-ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-61 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=121; Lactate dehydrogenase (U/L)=321; FERRITIN (ng/mL)=322; PCR (mg/dL)=2.24; RAW_FILE_NAME(Raw_File_Name)=CAR-61 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-61 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=119; Lactate dehydrogenase (U/L)=234; FERRITIN (ng/mL)=90; PCR (mg/dL)=0.13; RAW_FILE_NAME(Raw_File_Name)=CAR-61 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-61 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-61 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR61-ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PD; TRIGLYCERIDES (mg/dL)=190; Lactate dehydrogenase (U/L)=535; FERRITIN (ng/mL)=284; PCR (mg/dL)=1.95; RAW_FILE_NAME(Raw_File_Name)=CAR61-ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-65 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=74; Lactate dehydrogenase (U/L)=191; FERRITIN (ng/mL)=375; PCR (mg/dL)=0.69; RAW_FILE_NAME(Raw_File_Name)=CAR-65 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-65 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=101; Lactate dehydrogenase (U/L)=298; FERRITIN (ng/mL)=151; PCR (mg/dL)=0.13; RAW_FILE_NAME(Raw_File_Name)=CAR-65 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-65 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-65 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR65-ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=78; Lactate dehydrogenase (U/L)=187; FERRITIN (ng/mL)=283; PCR (mg/dL)=0.23; RAW_FILE_NAME(Raw_File_Name)=CAR65-ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-66 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=162; Lactate dehydrogenase (U/L)=300; FERRITIN (ng/mL)=87; PCR (mg/dL)=1.81; RAW_FILE_NAME(Raw_File_Name)=CAR-66 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-66 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=932; Lactate dehydrogenase (U/L)=437; FERRITIN (ng/mL)=55; PCR (mg/dL)=0.04; RAW_FILE_NAME(Raw_File_Name)=CAR-66 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-66 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-66 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR66-ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=173; Lactate dehydrogenase (U/L)=313; FERRITIN (ng/mL)=88; PCR (mg/dL)=1.19; RAW_FILE_NAME(Raw_File_Name)=CAR66-ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-69 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=242; Lactate dehydrogenase (U/L)=178; FERRITIN (ng/mL)=1191; PCR (mg/dL)=1.81; RAW_FILE_NAME(Raw_File_Name)=CAR-69 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-69 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=237; Lactate dehydrogenase (U/L)=168; FERRITIN (ng/mL)=73; PCR (mg/dL)=0.13; RAW_FILE_NAME(Raw_File_Name)=CAR-69 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-69 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-69 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR-69 ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=365; Lactate dehydrogenase (U/L)=205; FERRITIN (ng/mL)=498; PCR (mg/dL)=0.44; RAW_FILE_NAME(Raw_File_Name)=CAR-69 ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-71 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=108; Lactate dehydrogenase (U/L)=181; FERRITIN (ng/mL)=99; PCR (mg/dL)=5.1; RAW_FILE_NAME(Raw_File_Name)=CAR-71 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-71 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=79; Lactate dehydrogenase (U/L)=244; FERRITIN (ng/mL)=22; PCR (mg/dL)=5.73; RAW_FILE_NAME(Raw_File_Name)=CAR-71 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-71 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-71 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR-71 ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PD; TRIGLYCERIDES (mg/dL)=140; Lactate dehydrogenase (U/L)=192; FERRITIN (ng/mL)=39; PCR (mg/dL)=0.88; RAW_FILE_NAME(Raw_File_Name)=CAR-71 ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-72 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=125; Lactate dehydrogenase (U/L)=150; FERRITIN (ng/mL)=650; PCR (mg/dL)=4.31; RAW_FILE_NAME(Raw_File_Name)=CAR-72 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-72 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=141; Lactate dehydrogenase (U/L)=156; FERRITIN (ng/mL)=584; PCR (mg/dL)=2.22; RAW_FILE_NAME(Raw_File_Name)=CAR-72 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-72 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-72 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR-72 ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=No toxicity; Follow up=PD; TRIGLYCERIDES (mg/dL)=110; Lactate dehydrogenase (U/L)=161; FERRITIN (ng/mL)=598; PCR (mg/dL)=2.29; RAW_FILE_NAME(Raw_File_Name)=CAR-72 ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-75 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PR; TRIGLYCERIDES (mg/dL)=152; Lactate dehydrogenase (U/L)=143; FERRITIN (ng/mL)=270; PCR (mg/dL)=4.64; RAW_FILE_NAME(Raw_File_Name)=CAR-75 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-75 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PR; TRIGLYCERIDES (mg/dL)=160; Lactate dehydrogenase (U/L)=240; FERRITIN (ng/mL)=2130; PCR (mg/dL)=3.52; RAW_FILE_NAME(Raw_File_Name)=CAR-75 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-75 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PR; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-75 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR-75 ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=PR; TRIGLYCERIDES (mg/dL)=249; Lactate dehydrogenase (U/L)=221; FERRITIN (ng/mL)=195; PCR (mg/dL)=3.87; RAW_FILE_NAME(Raw_File_Name)=CAR-75 ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-76 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=86; Lactate dehydrogenase (U/L)=172; FERRITIN (ng/mL)=428; PCR (mg/dL)=1.42; RAW_FILE_NAME(Raw_File_Name)=CAR-76 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-76 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=134; Lactate dehydrogenase (U/L)=281; FERRITIN (ng/mL)=740; PCR (mg/dL)=0.05; RAW_FILE_NAME(Raw_File_Name)=CAR-76 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-76 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-76 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR-76 ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS; Follow up=CR; TRIGLYCERIDES (mg/dL)=97; Lactate dehydrogenase (U/L)=237; FERRITIN (ng/mL)=266; PCR (mg/dL)=1.27; RAW_FILE_NAME(Raw_File_Name)=CAR-76 ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-77 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=108; Lactate dehydrogenase (U/L)=167; FERRITIN (ng/mL)=315; PCR (mg/dL)=0.54; RAW_FILE_NAME(Raw_File_Name)=CAR-77 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-77 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=213; Lactate dehydrogenase (U/L)=221; FERRITIN (ng/mL)=410; PCR (mg/dL)=0.03; RAW_FILE_NAME(Raw_File_Name)=CAR-77 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-77 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-77 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR-77 ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:tisa-cell	Toxicity=CRS; Follow up=PR; TRIGLYCERIDES (mg/dL)=155; Lactate dehydrogenase (U/L)=181; FERRITIN (ng/mL)=365; PCR (mg/dL)=0.14; RAW_FILE_NAME(Raw_File_Name)=CAR-77 ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-83 ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=EDEMA; TRIGLYCERIDES (mg/dL)=117; Lactate dehydrogenase (U/L)=273; FERRITIN (ng/mL)=343; PCR (mg/dL)=2.08; RAW_FILE_NAME(Raw_File_Name)=CAR-83 ING
SUBJECT_SAMPLE_FACTORS           	-	CAR-92 +1D	Time point:After 1 Day post-infusion (1D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=95; Lactate dehydrogenase (U/L)=182; FERRITIN (ng/mL)=185; PCR (mg/dL)=1.16; RAW_FILE_NAME(Raw_File_Name)=CAR-92 +1D
SUBJECT_SAMPLE_FACTORS           	-	CAR-92 +30D	Time point:After 30 Days post-infusion (30D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=72; Lactate dehydrogenase (U/L)=326; FERRITIN (ng/mL)=25; PCR (mg/dL)=0.11; RAW_FILE_NAME(Raw_File_Name)=CAR-92 +30D
SUBJECT_SAMPLE_FACTORS           	-	CAR-92 +7D	Time point:After 7 Days post-infusion (7D) | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=0; Lactate dehydrogenase (U/L)=0; FERRITIN (ng/mL)=0; PCR (mg/dL)=0; RAW_FILE_NAME(Raw_File_Name)=CAR-92 +7D
SUBJECT_SAMPLE_FACTORS           	-	CAR-92 ING	Time point:Pre-lymphodepletion | Sample source:plasma | Therapy:axi-cell	Toxicity=CRS / ICANS; Follow up=CR; TRIGLYCERIDES (mg/dL)=93; Lactate dehydrogenase (U/L)=232; FERRITIN (ng/mL)=69; PCR (mg/dL)=0.2; RAW_FILE_NAME(Raw_File_Name)=CAR-92 ING
#COLLECTION
CO:COLLECTION_SUMMARY            	Blood samples were collected at the PLD time point and day +1 (D1), +7 (D7), and
CO:COLLECTION_SUMMARY            	+30 (D30) after CAR-T cell infusion, when available. Plasma separation was
CO:COLLECTION_SUMMARY            	performed by centrifugation at 1000xg for 15 minutes at room temperature. Plasma
CO:COLLECTION_SUMMARY            	aliquots were collected and stored at -80°C.
CO:SAMPLE_TYPE                   	Blood (plasma)
CO:STORAGE_CONDITIONS            	-80℃
#TREATMENT
TR:TREATMENT_SUMMARY             	This is a prospective observational tissue study performed in patients affected
TR:TREATMENT_SUMMARY             	by r/r B-NHL after CD19.CAR-T cell therapy with axi-cel and tisa-cel. Only
TR:TREATMENT_SUMMARY             	patients with diffuse large B‐cell lymphoma (DLBCL), DLBCL transformed from
TR:TREATMENT_SUMMARY             	follicular lymphoma (tFL), high-grade B-cell lymphoma (HGBCL), and primary
TR:TREATMENT_SUMMARY             	mediastinal B‐cell lymphoma (PMBCL) were included. Cytokine release syndrome
TR:TREATMENT_SUMMARY             	(CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) were
TR:TREATMENT_SUMMARY             	graded according to the American Society for Transplantation and Cellular
TR:TREATMENT_SUMMARY             	Therapy (ASCT) criteria. All eligible patients were treated at IRCCS AOU di
TR:TREATMENT_SUMMARY             	Bologna, after signing a written informed consent. The study was approved by the
TR:TREATMENT_SUMMARY             	local Ethical Committee in agreement with the Helsinki Declaration and
TR:TREATMENT_SUMMARY             	registered at clinicaltrial.gov NCT04892433. 44 patients with
TR:TREATMENT_SUMMARY             	relapsed/refractory B-cell non Hodgkin lymphoma (r/r/B-NHL) were infused with
TR:TREATMENT_SUMMARY             	approved CD19.CAR-T cell products at the time of pre-lymphodepletion (PLD) and
TR:TREATMENT_SUMMARY             	at day 1, 7, and 30 after CAR-T cell infusion. Other parameters as TRIGLYCERIDES
TR:TREATMENT_SUMMARY             	(mg/dL); Lactate dehydrogenase (LDH) (U/L); FERRITIN (ng/mL); PROTEIN C REACTIVE
TR:TREATMENT_SUMMARY             	(PCR) (mg/dL) are available for each patient. The follow up of patients are
TR:TREATMENT_SUMMARY             	indicated as Complete Remission (CR); Partial Disease (PD) and Partial Response
TR:TREATMENT_SUMMARY             	(PR).
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Plasma samples were thawed at room temperature and 5 mm NMR tubes were prepared
SP:SAMPLEPREP_SUMMARY            	for NMR measurement by adding 200 µL of sample with 400 µL of saline buffer
SP:SAMPLEPREP_SUMMARY            	solution at pH 7.4 (NaCl 0.9%, 50 mM of sodium phosphate buffer in D2O
SP:SAMPLEPREP_SUMMARY            	containing trimethylsilyl propionic-2,2,3,3-d4 acid sodium salt, TSP).
#ANALYSIS
AN:ANALYSIS_TYPE                 	NMR
AN:ANALYSIS_PROTOCOL_FILE        	NMR_analysis_protocol_file.pdf
#NMR
NM:INSTRUMENT_NAME               	Bruker Avance III NMR
NM:INSTRUMENT_TYPE               	FT-NMR
NM:NMR_EXPERIMENT_TYPE           	1D-1H
NM:SPECTROMETER_FREQUENCY        	600.13 MHz
NM:NMR_RESULTS_FILE               	ST003205_AN005257_Results.txt	UNITS:ppm
#END